Staphylococcus aureus leukocidin ED (LukED)

Staphylococcus aureus leukocidin ED (LukED) is a bicomponent pore-forming bacterial exotoxin produced by *S. aureus* as a virulence factor during systemic infection.[1][2] The toxin consists of two protein subunits (LukE and LukD) that together form membrane-damaging pores in host immune cells, particularly neutrophils, by targeting chemokine receptors CXCR1, CXCR2, and CCR5.[2] LukED plays a critical role in *S. aureus* pathogenesis by killing phagocytes recruited to sites of infection, thereby promoting bacterial survival and dissemination, especially in bloodstream infections and MRSA infections.[1][3] The toxin's expression is regulated by bacterial metabolic sensing mechanisms, including the RpiRc transcriptional regulator and the Agr-Rot regulatory network.[3] While LukED itself is not a conventional drug target, understanding its mechanism of action and regulation has identified potential therapeutic strategies, such as receptor antagonism or toxin inhibition, for treating severe *S. aureus* infections.[2]

As LukED is a bacterial virulence factor and not a conventional therapeutic target, there are no drugs with a defined mechanism of action against it. However, hypothetical therapeutic strategies would involve inhibiting LukED-receptor interactions or blocking pore formation to prevent cellular damage and reduce bacterial pathogenesis.